Literature DB >> 24092389

Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression.

Inbal Mishalian1, Rachel Bayuh, Liran Levy, Lida Zolotarov, Janna Michaeli, Zvi Gregorio Fridlender.   

Abstract

The role and characteristics of tumor-associated neutrophils (TAN) in cancer are poorly defined. We have recently shown that TAN can have anti-tumorigenic (N1) or pro-tumorigenic (N2) functions. An interesting unanswered question is how the phenotype of TAN is influenced by the ongoing evolvement of tumor microenvironment. We therefore studied the phenotype and effects of TAN at different time points during tumor progression. We used two models of murine tumor cancer cell lines-Lewis lung carcinoma (LLC) and AB12 (mesothelioma). Neutrophils were studied at early and late stages and compared to each other and to neutrophils from bone marrow/periphery of naïve mice. Although there was no difference in the number of neutrophils entering the tumor, we found that at early stages of tumor development, neutrophils were almost exclusively at the periphery of the tumor. Only at later stages, neutrophils were also found scattered among the tumor cells. We further found that TAN from early tumors are more cytotoxic toward tumor cells and produce higher levels of TNF-α, NO and H2O2. In established tumors, these functions are down-regulated and TAN acquire a more pro-tumorigenic phenotype. In line with this phenotype, only depletion of neutrophils at later stages of tumor development inhibited tumor growth, possibly due to their central location in the tumor. Our work adds another important layer to the understanding of neutrophils in cancer by further characterizing the changes in TAN during time. Additional research on the functional role of TAN and differences between subsets of TAN is currently underway.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24092389     DOI: 10.1007/s00262-013-1476-9

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  124 in total

Review 1.  Neutrophils in the Tumor Microenvironment.

Authors:  Davalyn R Powell; Anna Huttenlocher
Journal:  Trends Immunol       Date:  2015-12-14       Impact factor: 16.687

2.  Neutrophils Oppose Uterine Epithelial Carcinogenesis via Debridement of Hypoxic Tumor Cells.

Authors:  Adam Blaisdell; Amandine Crequer; Devin Columbus; Takiko Daikoku; Khush Mittal; Sudhansu K Dey; Adrian Erlebacher
Journal:  Cancer Cell       Date:  2015-12-14       Impact factor: 31.743

Review 3.  Neutrophils as Orchestrators in Tumor Development and Metastasis Formation.

Authors:  Lydia Kalafati; Ioannis Mitroulis; Panayotis Verginis; Triantafyllos Chavakis; Ioannis Kourtzelis
Journal:  Front Oncol       Date:  2020-12-10       Impact factor: 6.244

4.  Neutrophils Restrict Tumor-Associated Microbiota to Reduce Growth and Invasion of Colon Tumors in Mice.

Authors:  Daniel Triner; Samantha N Devenport; Sadeesh K Ramakrishnan; Xiaoya Ma; Ryan A Frieler; Joel K Greenson; Naohiro Inohara; Gabriel Nunez; Justin A Colacino; Richard M Mortensen; Yatrik M Shah
Journal:  Gastroenterology       Date:  2018-12-11       Impact factor: 22.682

Review 5.  Mouse versus Human Neutrophils in Cancer: A Major Knowledge Gap.

Authors:  Evgeniy B Eruslanov; Sunil Singhal; Steven M Albelda
Journal:  Trends Cancer       Date:  2017-01-19

6.  Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity.

Authors:  Akash Patnaik; Kenneth D Swanson; Eva Csizmadia; Aniruddh Solanki; Natalie Landon-Brace; Marina P Gehring; Katja Helenius; Brian M Olson; Athalia R Pyzer; Lily C Wang; Olivier Elemento; Jesse Novak; Thomas B Thornley; John M Asara; Laleh Montaser; Joshua J Timmons; Todd M Morgan; Yugang Wang; Elena Levantini; John G Clohessy; Kathleen Kelly; Pier Paolo Pandolfi; Jacalyn M Rosenblatt; David E Avigan; Huihui Ye; Jeffrey M Karp; Sabina Signoretti; Steven P Balk; Lewis C Cantley
Journal:  Cancer Discov       Date:  2017-03-08       Impact factor: 39.397

Review 7.  The barrier hypothesis and Oncostatin M: Restoration of epithelial barrier function as a novel therapeutic strategy for the treatment of type 2 inflammatory disease.

Authors:  Kathryn L Pothoven; Robert P Schleimer
Journal:  Tissue Barriers       Date:  2017-06-13

8.  Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination.

Authors:  Shelby Lennon; Ayman Oweida; Dallin Milner; Andy V Phan; Shilpa Bhatia; Benjamin Van Court; Laurel Darragh; Adam C Mueller; David Raben; Jorge L Martínez-Torrecuadrada; Todd M Pitts; Hilary Somerset; Kimberly R Jordan; Kirk C Hansen; Jason Williams; Wells A Messersmith; Richard D Schulick; Philip Owens; Karyn A Goodman; Sana D Karam
Journal:  Clin Cancer Res       Date:  2019-04-03       Impact factor: 12.531

9.  Dynamic interplay between tumour, stroma and immune system can drive or prevent tumour progression.

Authors:  R J Seager; Cynthia Hajal; Fabian Spill; Roger D Kamm; Muhammad H Zaman
Journal:  Converg Sci Phys Oncol       Date:  2017-07-28

10.  Priming of neutrophils toward NETosis promotes tumor growth.

Authors:  Mélanie Demers; Siu Ling Wong; Kimberly Martinod; Maureen Gallant; Jessica E Cabral; Yanming Wang; Denisa D Wagner
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.